Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.50 |
| ▸ | CA2 | P00918 | 8/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323438 | 0.87 | ALDH1A1 (0.61) | LMNAALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL17177605 | 0.82 | ALDH1A1 (0.53) | LMNAALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL394046 | 0.82 | LMNA (0.55) | CA1CA2CA9CA12LMNA | |
| SCHEMBL3660419 | 0.82 | HTT (0.56) | LMNAALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL1627692 | 0.81 | ALDH1A1 (0.51) | LMNAALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL24984042 | 0.81 | ALDH1A1 (0.54) | LMNAALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL16791126 | 0.80 | ALDH1A1 (0.53) | LMNAALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL18515898 | 0.80 | ALDH1A1 (0.53) | LMNAALDH1A1MAPK1L3MBTL1LTA4H | |
| SCHEMBL31626600 | 0.80 | LMNA (0.52) | CA1CA2CA9CA12LMNA | |
| SCHEMBL24119984 | 0.79 | ALDH1A1 (0.56) | LMNAALDH1A1MAPK1L3MBTL1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023044046-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | CA1 2550/4885CA2 3825/4885CA9 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.